Trial · NCT07588984
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
NCT07588984, Not yet recruiting, Noom Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study. Trials, record NCT07588984. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07588984
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
- NCT number
- NCT07588984
- Status
- Not yet recruiting
- Enrollment
- 2,310 participants, estimated
- Lead sponsor
- Noom Inc.
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
- Interventions
- Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
- First posted
- 2026-05-15
- Last updated
- 2026-05-15
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Body Weight | Monthly, Baseline through Month 12 (and Months 18 & 24 for FLOURISH GLP-1 arms) | Change from baseline in body weight (kg/lbs) measured via connected scale. |
| Primary | Change in fasting glucose | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in fasting glucose (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in HbA1c | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in HbA1c (mmol/mol and percentage) measured via Tasso+ capillary blood collection device. |
| Primary | Change in LDL cholesterol | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in LDL cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in HDL cholesterol | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in HDL cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in total cholesterol | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in total cholesterol (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in triglycerides | Baseline, Month 2, Month 4, Month 8, Month 12 | Change from baseline in triglycerides (milligrams per deciliter (mg/dL)) measured via Tasso+ capillary blood collection device. |
| Primary | Change in Body Composition | Monthly, Baseline through Month 12 ((and Months 18 & 24 for FLOURISH GLP-1 arms) | Change from baseline in estimated body composition metrics (lean mass, fat mass percentage) as measured via in-app BodyScan feature. |
| Primary | GLP-1 Side Effect Profile | Baseline (pre-treatment), Monthly through Month 12 | Number, severity, and tolerance of GLP-1 medication-related side effects (nausea, vomiting, diarrhea, constipation, headache, fatigue, injection site reactions) assessed via monthly self-report. Applicable to GLP-1 arms only. |
| Secondary | Change in heart rate variability (HRV) | Collected monthly from baseline through month 12 and at months 18 and 24 for the FLOURISH GLP-1 program. | Change in heart rate variability (HRV) from baseline measured via in-app FaceScan feature (all arms) and wearables (select arms). |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07588984
GET https://conductscience.org/api/trials/v1/NCT07588984/registered?page=2